PreveCeutical Medical Inc.

CA74141E1043

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 20:56:31 17/05/2024 BST			5-day change	1st Jan Change
0.025 ^CAD	0.00%		0.00%	0.00%

05-02	PreveCeutical Medical Inc. announced that it expects to receive CAD 0.25 million in funding	CI
2023	PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program	CI

PreveCeutical Medical Inc. announced that it expects to receive CAD 0.25 million in funding

May 01, 2024

PreveCeutical Medical Inc. announced a private placement for gross proceeds of up to CAD 250,000 on May 2, 2024.

Latest news about PreveCeutical Medical Inc.

PreveCeutical Medical Inc. announced that it expects to receive CAD 0.25 million in funding	05-01	CI
PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program	12-04	CI
PreveCeutical Medical Prepares For Proof of Concept Preclinical Study For Diabetes, Obesity Dual Gene Therapy Program	12-04	MT
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
PreveCeutical & Endosane Announce Update on Intranasal CBD Application	18/09/23	MT
PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD Application	18/09/23	CI
PreveCeutical Medical Inc. Showcases Dynamic Evolution in AI Strategy	12/09/23	CI
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/08/23	CI
PrevCeutical Medical Provides Update	24/07/23	MT
PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and Australia	24/07/23	CI
PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof	28/06/23	CI
Preveceutical Medical Inc. Furthering the Progress of Its Patent Family Directed to Sol-Gel	30/05/23	CI
PreveCeutical Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
PreveCeutical Medical Inc. Auditor Raises 'Going Concern' Doubt	30/04/23	CI
PreveCeutical Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/04/23	CI
PreveCeutical Medical Inc. Appoints Shawn Sadler as Head of Artificial Intelligence	24/04/23	CI
PreveCeutical Medical Inc. Launches Clinical Artificial Intelligence Division	24/04/23	CI
Preveceutical Medical Inc. Appoints C. Evan Ballantyne to the Board of Directors	21/02/23	CI
PreveCeutical Medical Inc. Signs Sol-Gel License Agreement with Its Subsidiary PreveCeutical Pty Ltd	09/01/23	CI
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/11/22	CI
Preveceutical Medical Inc. Announces Appointment of Kathleen Rotika to Board of Directors	20/10/22	CI
PreveCeutical Medical Inc. Announces Resignation of Sachin Nanavati as A Member of the Company's Board of Director, Effective September 16, 2022	15/09/22	CI
PreveCeutical Medical Inc. Appoints Mr. Sachin Nanavati to Board of Directors	06/09/22	CI
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/08/22	CI
PreveCeutical Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/05/22	CI

Chart PreveCeutical Medical Inc.

Duration

Period

More charts

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Companyâs principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Companyâs pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Companyâs subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.

Sector

Pharmaceuticals

Calendar

27/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PREVECEUTICAL MEDICAL INC.	0.00%	9.84M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B